As of 2026-03-16, the Intrinsic Value of Sartorius Stedim Biotech SA (DIM.PA) is 106.63 EUR. This DIM.PA valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 160.15 EUR, the upside of Sartorius Stedim Biotech SA is -33.40%.
The range of the Intrinsic Value is 71.36 - 192.35 EUR
Based on its market price of 160.15 EUR and our intrinsic valuation, Sartorius Stedim Biotech SA (DIM.PA) is overvalued by 33.40%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 71.36 - 192.35 | 106.63 | -33.4% |
| DCF (Growth 10y) | 98.73 - 244.39 | 141.52 | -11.6% |
| DCF (EBITDA 5y) | 95.87 - 158.69 | 121.42 | -24.2% |
| DCF (EBITDA 10y) | 120.56 - 202.55 | 153.63 | -4.1% |
| Fair Value | 42.82 - 42.82 | 42.82 | -73.26% |
| P/E | 66.47 - 123.13 | 87.32 | -45.5% |
| EV/EBITDA | 62.62 - 121.95 | 89.11 | -44.4% |
| EPV | 0.62 - 7.62 | 4.12 | -97.4% |
| DDM - Stable | 23.35 - 69.32 | 46.34 | -71.1% |
| DDM - Multi | 56.67 - 129.93 | 78.84 | -50.8% |
| Market Cap (mil) | 15,587.40 |
| Beta | 1.53 |
| Outstanding shares (mil) | 97.33 |
| Enterprise Value (mil) | 17,760.50 |
| Market risk premium | 5.82% |
| Cost of Equity | 9.37% |
| Cost of Debt | 5.36% |
| WACC | 8.62% |